Biologics Market Size, Share & Growth Analysis Report 2026–2034

The global biologics market is expanding rapidly as demand for advanced biological therapies increases across oncology, infectious diseases, immunological disorders, and other therapeutic areas. According to Straits Research, the global biologics market size was valued at USD 611.17 billion in 2025 and is projected to reach USD 1,441.11 billion by 2034, growing at a CAGR of 10% during the forecast period from 2026 to 2034. North America dominated the market with a 43% share in 2025, while Europe is projected to be the fastest-growing regional market.

Request Sample: https://straitsresearch.com/report/biologics-market/request-sample

Biologics Market Overview

Biologics are medical products derived from living organisms or biological sources and are used to prevent, treat, or manage various diseases. These products include vaccines, antibodies, cell and gene therapies, and recombinant proteins.

The market is supported by the growing prevalence of chronic diseases, advancements in biotechnology, increasing demand for targeted therapies, and rising investment in biopharmaceutical research and development. Increasing demand for personalized biologic therapies and continued investment in biologic drug development are also strengthening the development pipeline and manufacturing capabilities.

The global biologics market was valued at USD 611.17 billion in 2025 and is estimated to reach USD 672.29 billion in 2026. By 2034, the market is projected to reach USD 1,441.11 billion.

Biologics Market Size and Forecast

The biologics market is projected to grow at a CAGR of 10% from 2026 to 2034.

The market outlook reflects increasing demand for targeted biological therapies, expansion of biologic development pipelines, and growing manufacturing capabilities across major markets.

Biologics Market Drivers

Rising Demand for Personalized Biologic Therapies

The increasing demand for personalized biologic therapies is expanding the need for treatments tailored to specific patient and disease characteristics. Greater use of biomarker testing and patient stratification supports treatment selection based on individual biological profiles.

For example, biomarker testing can help identify cancer patients who may benefit from a specific monoclonal antibody therapy. Increasing demand for targeted treatment options is encouraging pharmaceutical companies to expand biologic development and manufacturing capabilities, supporting overall market growth.

Increasing Investment in Biologic Drug Development

Rising investment in biologic drug development is expanding the supply pipeline by supporting research, clinical trials, and manufacturing capabilities. Pharmaceutical companies and biotechnology firms are increasing investment in products such as monoclonal antibodies and recombinant proteins for oncology, autoimmune diseases, and other therapeutic areas.

A broader development pipeline increases the future availability of biologic products and strengthens production capacity, supporting continued market expansion.

Biologics Market Challenges

Complex Manufacturing and Production Processes

Biologics require controlled production conditions, multiple processing stages, and strict quality checks to maintain product consistency and safety. These complex requirements can increase manufacturing time, operational costs, and the risk of batch variability or production failure.

Limited access to specialized bioreactors, sterile processing systems, and advanced quality-control facilities can also restrict production capacity. High infrastructure costs and technical requirements may make facility development challenging, particularly for smaller manufacturers and emerging markets.

Supply Chain and Cold-Chain Constraints

Dependence on specialized cell-culture media, resins, filters, single-use components, and other inputs can expose manufacturers to supply interruptions. Shortages of single-use bioprocessing components have previously affected biopharmaceutical manufacturers, potentially delaying production and limiting reliable product availability.

Biologics also often require controlled temperature conditions during manufacturing, transportation, and storage. These requirements increase logistics complexity and can limit distribution in regions with unreliable cold-chain infrastructure.

Biologics Market Opportunities

Expansion into Veterinary Therapeutics

Veterinary pharmaceutical companies, animal-health providers, and biologics developers can target biologic therapies for companion animals and livestock. Companies such as Zoetis can expand revenue through specialized biologic products for animal diseases, creating opportunities beyond human therapeutics.

Development of Oral and Alternative-Route Biologics

The development of oral, inhaled, nasal, and other non-injectable biologic formats presents additional growth opportunities. Biopharmaceutical companies and drug-delivery technology providers can develop alternative delivery approaches that support licensing, formulation partnerships, and new product commercialization.

Companies such as Oramed Pharmaceuticals are developing oral delivery technologies, creating opportunities for further development of alternative biologic administration formats.

Biologics Market Segmentation

By Source

The mammalian segment accounted for 71% of the market in 2025 and is expected to grow at a CAGR of 8.1% during 2026–2034. Its position is supported by the established use of mammalian cell systems for producing complex biologics and their ability to facilitate appropriate protein folding and post-translational modifications.

By Manufacturing

The in-house segment accounted for 66% of the market in 2025 because it provides control over manufacturing processes, quality standards, and production capacity. Meanwhile, the outsourced segment is expected to grow at a CAGR of 8.6% during 2026–2034, driven by demand for specialized manufacturing capabilities, flexible production capacity, and external bioprocessing expertise.

By Product

Monoclonal antibodies represented the leading product segment, accounting for 45% of the market in 2025. Their extensive use across oncology, immunological disorders, and other therapeutic areas supports segment growth.

The antisense & RNAi therapeutics segment is expected to grow at a CAGR of 9.5% during 2026–2034, supported by increasing development of nucleic acid-based therapies and gene-expression modulation approaches.

By Disease Category

The oncology segment accounted for 36% of the market in 2025 and is projected to grow at a CAGR of 8.8% during 2026–2034. Extensive use of biologics in cancer treatment and continued development of targeted and immune-based therapies support segment growth.

By Type

The tumor necrosis factor (TNF) inhibitor segment accounted for 28% of the market in 2025. The interleukin-6 (IL-6) or interleukin-17 blocker segment is expected to grow at a CAGR of 8.5% during 2026–2034, driven by increasing use of biologic therapies targeting specific inflammatory pathways.

By Mode of Purchase

Prescription drugs accounted for 91% of the market in 2025 and are expected to grow at a CAGR of 7.9% during 2026–2034. The specialized nature of biologic therapies and their use under healthcare-provider supervision support the dominance of this segment.

By End Users

Hospitals accounted for 48% of the market in 2025, supported by their oncology, specialty care, infusion, and diagnostic infrastructure. The homecare segment is expected to grow at a CAGR of 9.1% during 2026–2034 as adoption of home-based treatment increases.

By Distribution Channel

Hospital pharmacies accounted for 52% of the market in 2025. The online pharmacy segment is expected to grow at a CAGR of 9.8% during 2026–2034, supported by increasing adoption of digital healthcare services and online medicine ordering and delivery.

Biologics Market Regional Analysis

North America

North America dominated the biologics market with a 43% share in 2025. The region benefits from continued biologic innovation in the United States and expanding biosimilar activity.

The United States market is expected to benefit from streamlined biosimilar development, while biologics accounted for 51% of total U.S. drug spending in 2024. Canada is expected to benefit from an aging population and increasing demand for treatments associated with age-related conditions.

Europe

Europe is projected to be the fastest-growing regional market, registering a CAGR of 8.9% during 2026–2034. The European biologics ecosystem is supported by growing biological medicine sales and increasing biosimilar authorizations.

The UK, Germany, and France are expected to contribute to regional development through biosimilar adoption, biopharmaceutical development, regulatory initiatives, and investment in biotherapies and bioproduction.

Asia Pacific

Asia Pacific accounted for 20% of the global biologics market in 2025. Expanding healthcare needs, population ageing, and growing biopharmaceutical capacity are supporting market development.

Japan, China, South Korea, and India are expected to contribute to regional growth through government support for biopharmaceutical development, biosimilars, advanced regenerative medicine, domestic manufacturing, and biotechnology initiatives.

Key Players in the Biologics Market

The global biologics market is moderately fragmented and includes multinational pharmaceutical companies, biotechnology companies, specialty biologics manufacturers, contract development and manufacturing organizations, and regional biopharmaceutical firms.

Key players include:

1. Bristol-Myers Squibb Company

2. Merck KGaA

3. Novartis AG

4. Novo Nordisk A/S

5. Pfizer Inc.

6. Johnson & Johnson Services Inc.

7. Hoffmann La Roche Ltd.

Companies compete based on clinical efficacy, product safety, research and development capabilities, manufacturing scale, regulatory expertise, product portfolios, intellectual property, and healthcare-provider relationships.

Recent Developments in the Biologics Market

In April 2026, Samsung Biologics expanded its global biologics manufacturing network by commissioning additional large-scale biomanufacturing capacity to support commercial production of monoclonal antibodies and other biologic therapies.

In February 2026, Lonza Group launched expanded biologics development and manufacturing services with enhanced mammalian cell culture capabilities for late-stage clinical and commercial production.

In October 2025, FUJIFILM Diosynth Biotechnologies expanded its CDMO capabilities through new biomanufacturing facilities dedicated to biologics, cell culture, and recombinant protein production.

In June 2025, Thermo Fisher Scientific expanded its biologics manufacturing services by introducing enhanced end-to-end CDMO solutions supporting biologic drug development and commercial manufacturing.

Conclusion

The global biologics market is positioned for substantial growth, increasing from USD 672.29 billion in 2026 to USD 1,441.11 billion by 2034 at a CAGR of 10%. Growing demand for personalized biologic therapies, increasing investment in biologic drug development, and advancements in biologic manufacturing are expected to support market expansion.

North America remains the dominant regional market, while Europe is expected to record the fastest growth during the forecast period. Mammalian systems, monoclonal antibodies, oncology applications, TNF inhibitors, prescription drugs, hospitals, and hospital pharmacies represent important segments of the market.

At the same time, complex manufacturing processes, infrastructure limitations, supply disruptions, and cold-chain requirements remain key challenges. Opportunities in veterinary therapeutics and alternative-route biologics provide additional avenues for market development.

The continued development of targeted therapies, biosimilars, advanced biologic manufacturing, and alternative delivery formats is expected to shape the future trajectory of the global biologics market through 2034.

Report: https://straitsresearch.com/report/biologics-market